Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05290675 · ClinicalTrials.gov registry record
Quantra QPlus Sample Type Comparison
A clinical trial of Coagulation Defect; Bleeding, sponsored by HemoSonics.
- Completed
- Registry status
- 50
- Enrollment target
- 1
- Study location
NCT05290675: Completed study of Coagulation Defect; Bleeding, sponsored by HemoSonics.
NCT05290675 is a study of Coagulation Defect; Bleeding that has completed, run by HemoSonics. The registered enrollment target is 50 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05290675, a study of Coagulation Defect; Bleeding, has completed, sponsored by HemoSonics.
- COMPLETED
- Registry status
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a single center prospective observational study to compare QPlus parameter measurements in arterial and venous blood samples collected in parallel from patients undergoing cardiac surgery.
Primary Outcome
Coagulation function assessed in two sample types
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Quantra QPlus System
Study Locations (1)
Ohio
- Ohio State University Wexner Medical Center - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2021-11-04 |
| Est. Completion | 2022-11-02 |
What the finished NCT05290675 record still lists
NCT05290675 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 50 participants, a relatively small participant target.
The record links to 1 condition, with Coagulation Defect; Bleeding appearing as the primary indexed condition, and to 1 intervention - of which Quantra QPlus System is the first listed.
NCT05290675 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT05290675 about?
NCT05290675 is a clinical study titled "Quantra QPlus Sample Type Comparison". This is a single center prospective observational study to compare QPlus parameter measurements in arterial and venous blood samples collected in parallel from patients undergoing cardiac surgery.
What is the current status of trial NCT05290675?
This trial is currently completed. The enrollment target is 50 participants. The study started on 2021-11-04. Estimated completion is 2022-11-02.
What conditions does trial NCT05290675 study?
This clinical trial studies the following conditions: Coagulation Defect; Bleeding.
What interventions are being tested in trial NCT05290675?
The interventions under investigation include: Quantra QPlus System (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT05290675?
This trial is sponsored by HemoSonics, which has 24 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05290675 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Coagulation Defect; Bleeding
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI